CommercialCoverageMedium impact
08.02.33, Guselkumab (Tremfya®) Injection for Intravenous Use
Independence Blue Cross·Rheumatology, Dermatology, Gastroenterology·Pharmacy
Effective date
Mar 24, 2025
We identified it
Jun 19, 2026
Summary
A new commercial policy (08.02.33) for Guselkumab (Tremfya®) injection for intravenous use has been created. This establishes coverage criteria and billing guidelines for this specialty medication used to treat autoimmune conditions.
Action Required
By March 24, 2025: Billing team must review the new Guselkumab (Tremfya®) IV injection policy at the provided URL to understand coverage criteria, prior authorization requirements, and proper billing procedures. Update billing protocols and inform providers who treat autoimmune conditions about any new requirements.